Akira Inoue

Affiliations: 
Neurosurgery Yamagata University, Yamagata-shi, Yamagata-ken, Japan 
Google:
"Akira Inoue"
Mean distance: 19.07 (cluster 24)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hosomi Y, Morita S, Sugawara S, et al. (2019) Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901488
Qian Y, Wu X, Yokoyama Y, et al. (2019) E-cad-Fc-Matrix Enhances Cancer Stem-Like Properties and Induces Mesenchymal Features in Colon Cancer Cells. Cancer Science
Mori M, Fujimori M, van Vliet LM, et al. (2019) Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601). Cancer
Sugawara S, Nakagawa K, Yamamoto N, et al. (2019) Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. International Journal of Clinical Oncology
Kikuchi K, Nozawa K, Yamazaki N, et al. (2018) Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. The Journal of Dermatology
Hosomi Y, Tanai C, Yoh K, et al. (2018) Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opinion On Pharmacotherapy
Tamai K, Mizushima T, Wu X, et al. (2018) Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment. Molecular Cancer Therapeutics
Inoue A, Mizushima T, Wu X, et al. (2018) A miR-29b Byproduct Sequence Exhibits Potent Tumor Suppressive Activities via Inhibition of NF-κB Signaling in KRAS Mutant Colon Cancer Cells. Molecular Cancer Therapeutics
Oizumi S, Sugawara S, Minato K, et al. (2018) Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitivemutations. Esmo Open. 3: e000313
Goto Y, Tanai C, Yoh K, et al. (2017) Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. Esmo Open. 2: e000214
See more...